Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care

Acta Psychiatrica Scandinavica

Volumn 132, Issue 2, 2015, Pages 109-121

  Moore, S ^a   Shiers, D ^b   Daly, B ^c   Mitchell, A J ^d   Gaughran, F ^e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL COLLEGE OF PSYCHIATRISTS   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

metabolic syndrome; mortality; physical health; physical illness; schizophrenia

Indexed keywords

DENTAL PROCEDURE; HEALTH CARE DISPARITY; HEALTH PROMOTION; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; ORGANIZATION AND MANAGEMENT; PROCEDURES; RISK FACTOR; SCHIZOPHRENIA; STANDARDS;

DENTAL CARE; HEALTH PROMOTION; HEALTHCARE DISPARITIES; HUMANS; LIFE EXPECTANCY; LONG-TERM CARE; RISK FACTORS; SCHIZOPHRENIA;

EID: 85027922822     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12431     Document Type: Article

References (115)

1. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014;10:425–448.
2. Von Hausswolff-Juhlin Y, Bjartveit M, Lindstrom E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl 2009;438:15–21.
3. Yasamy MT, McDaniell E, Saxena S. Living a healthy life with schizophrenia: paving the road to recovery. USA: World Federation for Mental Health, 2014.
4. World Health Organization. Mental health action plan 2013–2020. Switzerland: WHO Press, 2013. ISBN: 978 92 4 150602.
5. RCPsych eNewsletter, 2014. Available from: http://www.rcpsych.ac.uk/usefulresources/rcpsychenewsletters/enewsletters2014/september2014/publicmentalhealth.aspx [updated 2014; cited 12/01/2015].
6. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013;170:324–333.
7. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123–1131.
8. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 2015;72:334–341.
9. Fekadu A, Medhin G, Kebede D et al. Excess mortality in severe mental illness: 10-year population-based cohort study in rural Ethiopia. Br J Psychiatry 2015;206:289–296.
10. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011;131:101–104.
11. Hayes RD, Chang CK, Fernandes AC et al. Functional status and all-cause mortality in serious mental illness. PLoS ONE 2012;7:e44613.
12. Hayes RD, Chang CK, Fernandes A et al. Associations between symptoms and all-cause mortality in individuals with serious mental illness. J Psychosom Res 2012;72:114–119.
13. Nordentoft M, Wahlbeck K, Hallgren J et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PloS One 2013;8:e55176.
14. Mitchell AJ, Vancampfort D, Sweers K, Van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–a systematic review and meta-analysis. Schizophr Bull 2013;39:306–318.
15. Czernichow S, Mennen L, Bertrais S, Preziosi P, Hercberg S, Oppert JM. Relationships between changes in weight and changes in cardiovascular risk factors in middle-aged French subjects: effect of dieting. Int J Obes Relat Metab Disord 2002;26:1138–1143.
16. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007;116:317–333.
17. Potvin S, Marchand S. Hypoalgesia in schizophrenia is independent of antipsychotic drugs: a systematic quantitative review of experimental studies. Pain 2008;138:70–78.
18. Stubbs B, Mitchell AJ, De Hert M et al. The prevalence and moderators of clinical pain in people with schizophrenia: a systematic review and large scale meta-analysis. Schizophr Res 2014;160:1–8.
19. Kuritzky A, Mazeh D, Levi A. Headache in schizophrenic patients: a controlled study. Cephalalgia 1999;19:725–727.
20. De Hert M, Hudyana H, Dockx L et al. Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry 2011;26:34–44.
21. Schulte PFJ, MacCabe JH. Clozapine: gold standard treatment for refractory schizophrenia: now or never? In: Buckley PF, Gaugrhan F, eds. Treatment resistant schizophrenia; a clinical conundrum. Berlin/Heidelberg: Springer-Verlag, 2014:81–91.
22. Barnes TR, Drake MJ, Paton C. Nocturnal enuresis with antipsychotic medication. Br J Psychiatry 2012;200:7–9.
23. March D, Hatch SL, Morgan C et al. Psychosis and place. Epidemiol Rev 2008;30:84–100.
24. World Health Organisation. Hidden cities: unmasking and overcoming health inequities in urban settings. Switzerland: WHO Press, 2010. ISBN 978 92 1 132278 1.
25. Roick C, Fritz-Wieacker A, Matschinger H et al. Health habits of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2007;42:268–276.
26. Biswas A, Oh PI, Faulkner GE et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med 2015;162:123–132.
27. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606–2610.
28. CDC. Current cigarette smoking among adults—United States, 2005–2013. MMWR Morb Mortal Wkly Rep 2014;63:1108–1228.
29. Samele C, Patel M, Boydell J, Leese M, Wessely S, Murray R. Physical illness and lifestyle risk factors in people with their first presentation of psychosis. Soc Psychiatry Psychiatr Epidemiol 2007;42:117–124.
30. Martin JL, McLean G, Park J et al. Impact of socioeconomic deprivation on rate and cause of death in severe mental illness. BMC Psychiatry 2014;14:261.
31. Andreassen OA, Djurovic S, Thompson WK et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet 2013;92:197–209.
32. Alkelai A, Greenbaum L, Lupoli S et al. Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. PLoS ONE 2012;7:e29228.
33. Leonard BE, Schwarz M, Myint AM. The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol 2012;26:33–41.
34. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–1223.
35. Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079–1087.
36. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009;373:4–5.
37. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412–424.
38. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68:609–616.
39. Bartels SJ, Pratt SI, Aschbrenner KA et al. Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry 2015;172:344–352.
40. Green CA, Yarborough BJ, Leo MC et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry 2015;172:71–81.
41. Curtis J, Watkins A, Samaras K et al. RANZCP abstracts – keeping the body in mind for young people with early psychosis. Aust N Z J Psychiatry 2014;48(Suppl. 1):1–131.
42. Perez-Iglesias R, Martinez-Garcia O, Pardo-Garcia G et al. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol 2014;17:41–51.
43. Goncalves P, Araujo JR, Martel F. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol 2015;25:1–16.
44. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137–141.
45. Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004;161:361–363.
46. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273–281.
47. Cohen D, De Hert M. Endogenic and iatrogenic diabetes mellitus in drug-naive schizophrenia: the role of olanzapine and its place in the psychopharmacological treatment algorithm. Neuropsychopharmacology 2011;36:2368–2369.
48. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 2013;39:295–305.
49. Correll CU, Robinson DG, Schooler NR et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry 2014;71:1350–1363.
50. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med 2010;40:187–200.
51. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225–235.
52. Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 2011;22:660–670.
53. Tiihonen J, Lonnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620–627.
54. Hayes RD, Downs J, Chang CK et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull 2014;41:644–655.
55. Mitchell AJ, Malone D, Doebbeling CC. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry 2009;194:491–499.
56. Crawford MJ, Jayakumar S, Lemmey SJ et al. Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study. Br J Psychiatry 2014;205:473–477.
57. Kisely S, Smith M, Lawrence D, Cox M, Campbell LA, Maaten S. Inequitable access for mentally ill patients to some medically necessary procedures. Can Med Assoc J 2007;176:779–784.
58. Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 2000;283:506–511.
59. Laursen TM, Mortensen PB, MacCabe JH, Cohen D, Gasse C. Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. Psychol Med 2014;44:1625–1637.
60. Nasrallah HA, Meyer JM, Goff DC et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15–22.
61. Frayne SM, Halanych JH, Miller DR et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med 2005;165:2631–2638.
62. Vinogradova Y, Coupland C, Hippisley-Cox J, Whyte S, Penny C. Effects of severe mental illness on survival of people with diabetes. Br J Psychiatry 2010;197:272–277.
63. Chou FH, Tsai KY, Su CY, Lee CC. The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr Res. 2011;129:97–103.
64. Chang CK, Hayes RD, Broadbent MT et al. A cohort study on mental disorders, stage of cancer at diagnosis and subsequent survival. BMJ Open 2014;4:e004295.
65. Kisely S, Crowe E, Lawrence D. Cancer-related mortality in people with mental illness. JAMA Psychiatry 2013;70:209–217.
66. Cooke BK, Magas LT, Virgo KS, Feinberg B, Adityanjee A, Johnson FE. Appendectomy for appendicitis in patients with schizophrenia. Am J Surg 2007;193:41–48.
67. Stubbs B, Gaughran F, Mitchell AJ et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry 2015;37:126–133.
68. Tsai KY, Lee CC, Chou YM et al. The risks of major osteoporotic fractures in patients with schizophrenia: a population-based 10-year follow-up study. Schizophr Res 2014;159:322–328.
69. Buller LT, Best MJ, Klika AK, Barsoum WK. The influence of psychiatric comorbidity on perioperative outcomes following primary total hip and knee arthroplasty; a 17-year analysis of the national hospital discharge survey database. J Arthroplasty 2015;30:165–170.
70. Lord O, Malone D, Mitchell AJ. Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis. Gen Hosp Psychiatry 2010;32:519–543.
71. Mitchell AJ, Pereira IE, Yadegarfar M, Pepereke S, Mugadza V, Stubbs B. Breast cancer screening in women with mental illness: comparative meta-analysis of mammography uptake. Br J Psychiatry 2014;205:428–435.
72. Raja M, Azzoni A. Sexual behavior and sexual problems among patients with severe chronic psychoses. Eur Psychiatry 2003;18:70–76.
73. MacDonald S, Halliday J, Mac ET et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case-control study. Br J Psychiatry 2003;182:50–56.
74. Marques TR, Smith S, Bonaccorso S et al. Sexual dysfunction in people with prodromal or first-episode psychosis. Br J Psychiatry 2012;201:131–136.
75. Carey MP, Carey KB, Maisto SA, Gordon CM, Vanable PA. Prevalence and correlates of sexual activity and HIV-related risk behavior among psychiatric outpatients. J Consult Clin Psychol 2001;69:846–850.
76. DOH. Choosing better oral health: an oral health plan for England. London: Department of Health, HMSO, 2005.
77. Desvarieux M, Demmer RT, Rundek T et al. Relationship between periodontal disease, tooth loss, and carotid artery plaque: the oral infections and vascular disease epidemiology study (INVEST). Stroke 2003;34:2120–2125.
78. Matevosyan NR. Oral health of adults with serious mental illnesses: a review. Community Ment Health J 2010;46:553–562.
79. Kisely S, Quek LH, Pais J, Lalloo R, Johnson NW, Lawrence D. Advanced dental disease in people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 2011;199:187–193.
80. Griffiths J, Jones V, Leeman I et al. Guidelines: oral health for people with mental health problems. London: British Society for Disability and Oral Health, 2000.
81. Flammer E, Breier A, Steinert T. Oral health and hygiene among persons with severe mental illness. Psychiatr Serv 2009;60:1402; author reply -3.
82. McCreadie RG, Stevens H, Henderson J et al. The dental health of people with schizophrenia. Acta Psychiatr Scand 2004;110:306–310.
83. Kilbourne AM, Horvitz-Lennon M, Post EP et al. Oral health in Veterans Affairs patients diagnosed with serious mental illness. J Public Health Dent 2007;67:42–48.
84. Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients’ subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003;36:105–112.
85. Stiefel DJ, Truelove EL, Menard TW, Anderson VK, Doyle PE, Mandel LS. A comparison of the oral health of persons with and without chronic mental illness in community settings. Spec Care Dentist 1990;10:6–12.
86. Shiers DE, Rafi I, Cooper SJ, Holt RIG. Positive cardiometabolic health resource: an intervention framework for patients with psychosis and schizophrenia. London: Royal College of Psychiatrists, 2014.
87. Bartels SJ. Can behavioral health organizations change health behaviors? The STRIDE study and lifestyle interventions for obesity in serious mental illness. Am J Psychiatry 2015;172:9–11.
88. Great Britain Parliament. Equality Act 2010: Elizabeth II. 2010.
89. Kozubal DE, Samus QM, Bakare AA et al. Separate may not be equal: a preliminary investigation of clinical correlates of electronic psychiatric record accessibility in academic medical centers. Int J Med Inform 2013;82:260–267.
90. Lester H. Shared care for people with mental illness: a GP's perspective. Adv Psychiatr Treat 2005;11:133–139.
91. Morcos S. Where are the weakest links?: a descriptive study of discrepancies in prescribing between primary and secondary sectors of mental health service provision. Psychiatr Bull 2002;26:371–374.
92. Procyshyn RM, Barr AM, Brickell T, Honer WG. Medication errors in psychiatry: a comprehensive review. CNS Drugs 2010;24:595–609.
93. Mueller SK, Kripalani S, Stein J et al. A toolkit to disseminate best practices in inpatient medication reconciliation: multi-center medication reconciliation quality improvement study (MARQUIS). Jt Comm J Qual Patient Saf 2013;39:371–382.
94. Health and Social Care Information Centre. Mental Health Bulletin, Annual Report from MHMDS Returns – 2013–14. Leeds: Health and Social Care Information Centre, 2014.
95. Meiklejohn C, Sanders K, Butler S. Physical health care in medium secure services. Nurs Stand 2003;17:33–37.
96. British Medical Association. Recognising the importance of physical health in mental health and intellectual disability; achieving parity of outcomes. London: British Medical Association, 2014.
97. Lester H. The James Mackenzie Lecture 2012: bothering about Billy. Br J Gen Pract 2013;63:e232–e234.
98. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012;140:159–168.
99. Banham L, Gilbody S. Smoking cessation in severe mental illness: what works? Addiction 2010;105:1176–1189.
100. O'Brien C, Gardner-Sood P, Corlett SK et al. Provision of health promotion programmes to people with serious mental illness: a mapping exercise of four South London boroughs. J Psychiatr Ment Health Nurs 2014;21:121–127.
101. De Hert M, Vancampfort D, Correll CU et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011;199:99–105.
102. National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: treatment and management. London: NICE, 2014; Clinical Guideline 178.
103. American Diabetes A, American Psychiatric A, American Association of Clinical E, North American Association for the Study of O. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601.
104. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009;32:1037–1042.
105. Patel MX, Bishara D, Jayakumar S et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol 2014;24:499–509.
106. Robinson DG, Schooler NR, John M et al. Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry 2015;172:237–248.
107. Buchanan RW, Kreyenbuhl J, Kelly DL et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71–93.
108. Lynch U, Lazenbatt A, Freeman R, Lynch G, Neill EO. Making equity a reality: oral health promotion in a psychiatric setting. Int J Psychiatr Nurs Res 2005;10:1078–1092.
109. Public Health England. Delivering better oral health: an evidence-based toolkit for prevention, 3rd edn. London: Public Health England, 2014.
110. Hede B. Dental health behavior and self-reported dental health problems among hospitalized psychiatric patients in Denmark. Acta Odontol Scand 1995;53:35–40.
111. Almomani F, Williams K, Catley D, Brown C. Effects of an oral health promotion program in people with mental illness. J Dent Res 2009;88:648–652.
112. Jones HF, Adams CE, Clifton A et al. An oral health intervention for people with serious mental illness (Three Shires Early Intervention Dental Trial): study protocol for a randomised controlled trial. Trials 2013;14:158.
113. Maj M. Physical health care in persons with severe mental illness: a public health and ethical priority. World Psychiatry 2009;8:1–2.
114. De Hert M, Correll CU, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52–77.
115. De Hert M, Cohen D, Bobes J et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10:138–151.